参考文献
(在框内滑动手指即可浏览)
[1] Mamtani A, Andrea V, Tari A, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study[J]. Ann Surg Oncol, 2016, 23(11): 3467-3474.
[2] 王永胜. 乳腺癌新辅助化疗的进展和热点讨论—标准与挑战[J]. 中国临床肿瘤学进展, 2015, 8(1): 143-146.
[3] 毕钊, 丛斌斌, 王永胜, 等. 分子分型与乳腺癌新辅助化疗腋窝降阶梯手术的研究[J].中国肿瘤临床, 2018, 45(8):6-9.
[4] 石志强, 邱鹏飞, 王永胜, 等. 乳腺癌新辅助化疗后选择性避免乳房手术的研究进展[J]. 中国癌症杂志, 2018, 28(8):609-613
[5] 中国乳腺癌新辅助治疗专家组. 中国乳腺癌新辅助治疗专家共识(2019年版). 中国癌症杂志, 2019, 29(5): 390-400.
[6] Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol,2021.Doi: 10.1016/j.annonc.2021.06.023.[Online ahead of print].
[7] Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
[8] APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2):122-131.
[9] Slamon DJ, Eiermann W, Robert NJ, et al. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 early breast cancer[J]. Cancer Res, 2016, 76(suppl4): 5-04.
[10] van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study[J]. Breast, 2016, 29:153-159.
[11] Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer[J]. Breast Cancer Res Treat, 2017, 165(3):593-600.
[12] Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis[J]. Ann Oncol,2018,29(7):1497-1508.
[13] Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9):810-821.
[14] Gianni L, Cs H, Egle D, et al. Pathological complete response to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP a PDL1 michelangelo randomized study[J]. Cancer Res, 2020, 80(1): abstr 03-04.
[15] NCCN Clinical Practice Guidelines in Oncology-Breast Cancer (Version 5 2021) [EB/OL]. [2021-07-10].https://www./professionals/physician_gls/default.aspx.
[16] Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline[J]. J Clin Oncol, 2021, 39(13):1485-1505.
[17] Smith I, Robertson J, Kilburn L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(11):1443-1454.
[18] Kim HJ, Noh WC, Lee ES, et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer[J]. Breast Cancer Res, 2020, 22(1):54-63.
[19] Han S, Choi JY. Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res, 2020, 22(1):119-134.
[20] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC polled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[21] 王玮,吴佳毅,沈坤炜.乳腺癌新辅助治疗几个热点问题[J].中国实用外科杂志,2015,35(7):709-713.
[22] von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7):617-628.
[23] Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(3):367-377.
[24] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy[J]. N Engl J Med, 2017, 376(22):2147-2159.
[25] Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J]. Cancer, 2007, 110(2):244-254.
[26] Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2 /HR- phase Ⅱ trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel[J]. Ann Oncol, 2017, 28(11):2768-2772.
[27] Sanford RA, Lei X, Barcenas CH, et al. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients[J]. Ann Surg Oncol, 2016, 23: 1515-1521.
[28] Loibl S, Werutsky G, Nekljudova V, et al. Abstract: impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials[J]. J Clin Oncol, 2017, 35(suppl 15):571.
[29] Omarini C, Guaitoli G, Noventa S,et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients[J]. Eur J Surg Oncol, 2017, 43(4): 613-618.
[30] Ditsch N, Kolberg-Liedtke C, Friedrich M, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2021[J]. Breast Care (Basel),2021,16(3):214-227.
[31] Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism[J]. Sci Transl Med, 2017, 9(397): eaan0026.
[32] Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models[J]. Nat Cell Biol, 2019, 21(2):190-202.
[33] Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis[J]. J Natl Cancer Inst, 2005, 97: 188-194.
[34] Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26: 778-785.
[35] Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla[J]. Breast Cancer, 2019, 26(3):373-377.
[36] Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305:569-575.
[37] Mila D, Geertjan T, Marieke ES, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12):1303-1310.
[38] Krag DN, Anderson SJ, Julian TB. et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10): 908-909.
[39] Brackstone M, Baldassarre FG, Perera FE, et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline[J]. J Clin Oncol, 2021, JCO2100934.
[40] Moo TA, Edelweiss M, Hajiyeva S, et al Is Low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? [J]. Ann Surg Oncol, 2018, 25(6):1488-1494.
[41] Almahariq MF, Levitin R, Quinn TJ, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2021, 28(2):930-940.